John LaMattina

Showing 6 posts of 6 posts found.

FDA image

FDA approvals: 1996 versus 2014

January 12, 2015
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, John LaMattina, LaMattina, NDA, US, appovals, drugs

As highlighted in a number of recent stories, 2014 was a banner year for the biopharmaceutical industry with 41 new …

LaMattina image

Drug prices defy gravity – until patent expiry

June 23, 2014
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing John LaMattina, LaMattina, Pfizer, drug, pharma, pricing, research

How drugs are priced is a hot topic these days, and a new Bloomberg article will cause it to heat-up …

John LaMattina

John LaMattina: Pharma’s R&D deals with foundations may hit reputations

June 17, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing John LaMattina

On the surface, it sounds pretty reasonable. Foundations like the Michael J. Fox Foundation and the Cystic Fibrosis Foundation (CFF), …

LaMattina image

John LaMattina: Pharma’s reputation continues to suffer – what can be done to fix it?

February 21, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bad pharma, Goldacre, John LaMattina, industry, transparency

You don’t have too look far to find unflattering articles about the pharmaceutical industry. What was previously the domain of …

lamattina_web

John LaMattina: Why was bapineuzamab moved into Phase III trials?

September 24, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AD, John LaMattina, Pfizer, bapineuzamab

The recent news that the Pfizer/J&J Alzheimer’s Disease drug, bapineuzumab (bapi), had failed in critical clinical trials resulted in great …

LaMattina image

John LaMattina: FDA tries to disavow role in higher hurdles for new drugs

July 2, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, John LaMattina, Pfizer, US, discovery, drug

As evidenced by various blog posts that I have written over the past year (e.g., “Why Doesn’t the FDA Get …

The Gateway to Local Adoption Series

Latest content